Integrating Data Mining with Transcranial Focused Ultrasound to Refine Neuralgia Treatment Strategies

The heterogeneity in the causes and responses to pain in patients makes neuralgia, a condition defined by persistent severe nerve pain, a challenging treatment problem. However, inconsistent therapeutic results and long patient suffering are common results of traditional therapy procedures that depend on generic methodologies. This research presents a technological framework that combines data mining and transcranial focused ultrasound (tFUS) to improve strategies for the treatment of neuralgia, with the aim of overcoming these limitations. The first step of the proposed system is to gather multimodal datasets that have been preprocessed using normalization, noise reduction, and feature extraction methods. These data sets include patient-reported pain ratings, clinical history, and brain imaging (fMRI, EEG). Next, data mining algorithms such as clustering and classification are used to find patterns of brain activity and pain attributes. Dimensionality reduction methods such as variational autoencoders (VAEs) make complex associations easier to observe and understand. Optimal tFUS parameters frequency, intensity, and focal depth are predicted for individual patients using machine learning models (MLM), such as gradient-boosted decision trees (GBDT) and Random Forests (RF). Based on the biomarkers detected, these predictions direct the deployment of tFUS procedures to a specific area of the brain. During treatment, real-time neural feedback systems track patients’ reactions, allowing adaptive alterations to boost effectiveness. Incorporating post-treatment results into an iterative feedback loop allows the continued improvement of prediction models for future sessions. An increase in pain reduction measures was observed compared to traditional techniques, greater neuroplasticity and fewer side effects when the framework was evaluated on data sets from patients with neuralgia. The proposed method achieves neuroplasticity by 97.86% and 97.14%, side effects of 34.61% and 37.83%, pain reduction of 98.64% and 96.36%, effectiveness and patient safety of 97.04% and 98.67%.